drugset
Drugs / NK immunotherapy
last change May 2020 re-read 2 minutes ago

NK immunotherapy

Cell therapy

Developed for
cancer · B-cell non-Hodgkin lymphoma · breast carcinoma · esophageal cancer · larynx cancer · non-small cell lung carcinoma · pharynx cancer · renal cell carcinoma
+1 more · tongue cancer
Investigated by
Fuda Cancer Hospital, Guangzhou · Shenzhen Hank Bioengineering Institute

Trials 12 · a red edge is where a trial was stopped

today NCT02857920 · Ph 1/2 NCT02849379 · Ph 1/2 NCT02853903 · Ph 2 NCT02843581 · Ph 1/2 NCT02843126 · Ph 1/2 NCT02849327 · Ph 1/2 NCT02843061 · Ph 1/2 NCT02849314 · Ph 1/2 NCT02845856 · Ph 1/2 NCT02843204 · Ph 1/2 NCT02849340 · Ph 1/2 NCT02843607 · Ph 1/2
2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/211 trials
Phase 1/2 NCT02857920 Aug 2016 → Aug 2017 cancer Fuda Cancer Hospital, Guangzhou Completed No outcome recorded
Phase 1/2 NCT02849379 Jul 2016 → Jul 2017 tongue cancer Fuda Cancer Hospital, Guangzhou Completed No outcome recorded
Phase 1/2 NCT02843581 Jul 2016 → Jul 2017 esophageal cancer Fuda Cancer Hospital, Guangzhou Completed No outcome recorded
Phase 1/2 NCT02843126 Jul 2016 → Jul 2017 breast carcinoma Fuda Cancer Hospital, Guangzhou Completed No outcome recorded
Phase 1/2 NCT02849327 Jul 2016 → Jul 2017 pharynx cancer Fuda Cancer Hospital, Guangzhou Completed No outcome recorded
Phase 1/2 NCT02843061 Jul 2016 → Jul 2017 B-cell non-Hodgkin lymphoma Fuda Cancer Hospital, Guangzhou Completed No outcome recorded
Phase 1/2 NCT02849314 Jul 2016 → Jul 2017 larynx cancer Fuda Cancer Hospital, Guangzhou Completed No outcome recorded
Phase 1/2 NCT02845856 Jul 2016 → Jul 2017 non-small cell lung carcinoma Fuda Cancer Hospital, Guangzhou Completed No outcome recorded
Phase 1/2 NCT02843204 Jul 2016 → Jul 2017 cancer Fuda Cancer Hospital, Guangzhou Completed No outcome recorded
Phase 1/2 NCT02849340 Jul 2016 → Jul 2017 — Fuda Cancer Hospital, Guangzhou Completed No outcome recorded
Phase 21 trial
Phase 2 NCT02853903 Jul 2016 → Jul 2017 cancer Fuda Cancer Hospital, Guangzhou Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

FieldValueCited text
Known as NK immunotherapy ClinicalTrials.gov intervention name — accepted as the source's own label NCT02853903 ↗
11

NCT02843204 ↗

NCT02849340 ↗

NCT02843126 ↗

NCT02845856 ↗

NCT02857920 ↗

NCT02849379 ↗

NCT02843061 ↗

NCT02843607 ↗

NCT02849327 ↗

NCT02849314 ↗

NCT02843581 ↗
Modality Cell therapy “The patients in group A continuously received 2 cycles of NK cell therapy as 1 course of treatment.” PMID 32027620 ↗ May 2020
Route Intravenous “Each treatment: about 10 billion cells in all, infusion in 3 times, i.v.” NCT02843204 ↗